<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04559919</url>
  </required_header>
  <id_info>
    <org_study_id>2020-00853</org_study_id>
    <nct_id>NCT04559919</nct_id>
  </id_info>
  <brief_title>Prospective Regional Epilepsy Database</brief_title>
  <acronym>PREDICT</acronym>
  <official_title>Prospective Regional Epilepsy Database and Biobank for Individualized Clinical Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PREDICT is an observational study following adults with an unprovoked seizure or epilepsy in&#xD;
      the health care region of western Sweden. The objective is to identify biomarkers and/or&#xD;
      genetic predisposition of relevance for diagnosis and/or treatment of epilepsy and study the&#xD;
      long-term prognosis and consequences of epilepsy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adults over 18 years of age, with an unprovoked seizure in the last year or epilepsy,&#xD;
      resident in the health care region of western Sweden (VGR) at the time of inclusion.&#xD;
&#xD;
      Baseline data and outcome variables are collected from several patient registries: the&#xD;
      electronic medical records system in the health care region VGR and Swedish National&#xD;
      Registers of healthcare, income, and employment managed by The National Board of Health and&#xD;
      Welfare or Statistics Sweden, both of which are government agencies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2031</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2031</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>epilepsy</measure>
    <time_frame>baseline and years 1,2,3,4,5,6,7,8,9,10</time_frame>
    <description>more than one seizure after first seizure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>seizure status</measure>
    <time_frame>baseline and years 1,2,3,4,5,6,7,8,9,10</time_frame>
    <description>the number of seizures in last two months and overall</description>
  </primary_outcome>
  <primary_outcome>
    <measure>drug resistant epilepsy</measure>
    <time_frame>baseline and years 1,2,3,4,5,6,7,8,9,10</time_frame>
    <description>epilepsy that has not responded to two antiepileptic drugs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>severe side effects of antiepileptic drug</measure>
    <time_frame>baseline and years 1,2,3,4,5,6,7,8,9,10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>psychosocial outcomes</measure>
    <time_frame>baseline and years 1,2,3,4,5,6,7,8,9,10</time_frame>
    <description>employment, marital status, income, sick leave</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>received health care</measure>
    <time_frame>baseline and years 1,2,3,4,5,6,7,8,9,10</time_frame>
    <description>the number of visits for epilepsy, missed appointments, time intervals between visits</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Adults with epilepsy</arm_group_label>
    <description>Adults over 18 years of age, with an unprovoked seizure in the last year or epilepsy, resident in VGR at the time of inclusion.&#xD;
Based on the clinical information, patients can be categorized into relevant groups; single seizure, seizure-free with epilepsy, and drug-resistant epilepsy. Subgroups may also be selected based on age, sex, epilepsy sub-diagnosis, cause of epilepsy, use of a particular antiepileptic drug, or experience of a particular side effect.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Seizure status</intervention_name>
    <description>We will collect information on first seizure ever, last seizure ever, number of seizure in last two months.</description>
    <arm_group_label>Adults with epilepsy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Tests</intervention_name>
    <description>We will collect results from imaging, electroencephalogram, and laboratory tests.</description>
    <arm_group_label>Adults with epilepsy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Epilepsy</intervention_name>
    <description>We will collect information on risk factors of epilepsy, cause of epilepsy, epilepsy type/syndrome, medications tried, if the epilepsy is drug resistent, side effects of antiepileptic drugs.</description>
    <arm_group_label>Adults with epilepsy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Demographics and psychosocial</intervention_name>
    <description>We will collect information on age, sex, date of death if applicable, marital status, education level, income type, driving status, employment, benefits, sick leave, number of household members.</description>
    <arm_group_label>Adults with epilepsy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Health care</intervention_name>
    <description>We will collect information on received health care; visit dates, caregiver, dispensation dates of antiepileptic drugs</description>
    <arm_group_label>Adults with epilepsy</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples, and for some individuals cerebrospinal fluid (if lumbar puncture is indicated&#xD;
      for clinical reasons, extra csf will be collected).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with an unprovoked seizure or epilepsy, resident in VGR at inclusion.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Over 18 years of age&#xD;
&#xD;
          -  An unprovoked seizure within the last year or a diagnosis of epilepsy according to the&#xD;
             current International League Against Epilepsy definition (epilepsy with seizure in the&#xD;
             last ten or antiepileptic drug treatment in the last five years)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Expected survival less than two years&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johan Zelano, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgrenska University Hospital, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johan Zelano, MD PhD</last_name>
    <phone>+46313421000</phone>
    <email>johan.zelano@vgregion.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Södra Älvsborgs Sjukhus</name>
      <address>
        <city>Borås</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Markus Karlander, MD</last_name>
      <email>markus.karlander@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Zelano, MD</last_name>
      <email>johan.zelano@vgregion.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 8, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Johan Zelano</investigator_full_name>
    <investigator_title>Consultant Neurologist</investigator_title>
  </responsible_party>
  <keyword>epilepsy</keyword>
  <keyword>biomarker</keyword>
  <keyword>access to care</keyword>
  <keyword>quality of care</keyword>
  <keyword>seizure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The data will be protected by privacy laws and cannot be shared even if anonymized, because of the high resolution of data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

